Provided by Tiger Trade Technology Pte. Ltd.

Jaguar Animal Health

0.2099
-0.0147-6.54%
Volume:408.87K
Turnover:87.42K
Market Cap:1.08M
PE:0.00
High:0.2350
Open:0.2350
Low:0.2093
Close:0.2246
52wk High:77.63
52wk Low:0.1999
Shares:5.17M
Float Shares:4.88M
Volume Ratio:1.08
T/O Rate:8.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-155.8774
EPS(LYR):-803.9466
ROE:-548.83%
ROA:-38.04%
PB:0.16
PE(LYR):0.00

Loading ...

Jaguar Health delays quarterly report filing after subsequent event transaction review

Reuters
·
May 19

Jaguar Health wins Nasdaq extension to regain $1 bid price compliance by May 18

Reuters
·
May 08

Jaguar Health discusses FDA breakthrough pathway for crofelemer in pediatric MVID trial

Reuters
·
May 06

Jaguar Animal Health Faces New Nasdaq Compliance Deficiency

TIPRANKS
·
May 04

Jaguar Health risks Nasdaq delisting after reverse split cuts public float below 500,000 shares

Reuters
·
May 04

Jaguar Animal Health trading halted, news pending

TIPRANKS
·
Apr 30

Jaguar Health announces results from trial of crofelemer

TIPRANKS
·
Apr 29

Jaguar Health says crofelemer trial meets primary endpoint in dogs with chemotherapy-induced diarrhea

Reuters
·
Apr 29

Jaguar Health granted extension to demonstrate compliance with Nasdaq bid rule

TIPRANKS
·
Apr 27

Jaguar Health executes 1-for-35 reverse stock split effective April 30

Reuters
·
Apr 27

Jaguar Health reports acceptance of abstracts on crofelemer for ESPGHAN meeting

TIPRANKS
·
Apr 24

Jaguar Health says two late-breaking pediatric intestinal failure crofelemer abstracts accepted at ESPGHAN

Reuters
·
Apr 24

Jaguar Health plans AI platforms to advance crofelemer clinical development for intestinal failure

Reuters
·
Apr 13

Jaguar Health hosts investor webcast on Q4 2025 financials and company updates

Reuters
·
Apr 10

Jaguar Animal Health Regains Nasdaq Compliance Through Capital Infusions

TIPRANKS
·
Apr 10

Jaguar Health completes effectiveness study of crofelemer tablets

TIPRANKS
·
Apr 08

Jaguar Health completes dog trial to support full FDA approval for Canalevia-CA1

Reuters
·
Apr 08

Jaguar Health FY25 net loss widens 37.6% to $54 million

Reuters
·
Apr 07

Jaguar Health says crofelemer study cuts pediatric intestinal failure parenteral support 12%-37%

Reuters
·
Apr 02

Jaguar Health unit Napo co-sponsors Elite Ped-GI Congress, spotlights crofelemer pediatric IF data

Reuters
·
Apr 02